Literature DB >> 27891422

Panvascular Disease in Familial Hypercholesterolaemia Treated with Endovascular Simultaneous Bilateral Carotid Stenting.

Anand Alurkar1, Lakshmi Sudha Prasanna Karanam2, Shripal Shah2, Pandurang Mare2.   

Abstract

Familial Hypercholesterolaemia (FH) is a monogenic autosomal dominant disorder affecting 1 in 500 individuals. We report a case of 32-year-old female with FH, previously not on any treatment, who presented with recurrent bilateral Middle Cerebral Artery (MCA) territory strokes and dyspnoea on exertion due to severe panvascualar disease involving descending aorta, innominate, subclavian, common carotid, internal carotid and coronary vessels. Her complete clinical work up was done and was started on lipid lowering drug treatment and low calorie diet. She underwent simultaneous bilateral carotid stenting followed by coronary artery bypass surgery at a later date. In the present scenario we want to emphasize the importance of early detection and treatment of individuals with FH, failing of which results in premature and accelerated atherosclerosis causing multisystemic vascular disease with significant morbidity and mortality. Screening of first degree relatives is important owing to the autosomal dominant inheritance pattern of the FH.

Entities:  

Keywords:  Atherosclerosis; Endovascular treatment; Stroke

Year:  2016        PMID: 27891422      PMCID: PMC5121760          DOI: 10.7860/JCDR/2016/19115.8594

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  9 in total

1.  On the diagnosis of heterozygous familial hypercholesterolaemia HFH.

Authors: 
Journal:  Int J Cardiol       Date:  2000-06-12       Impact factor: 4.164

2.  A suggestion for familial hypercholesterolemia (FH) heterozygosity clinical diagnosis based on epidemiological observations in a large Italian population.

Authors:  A Braiato; S D'Addato; Z Sangiorgi; A Gaddi
Journal:  Int J Cardiol       Date:  2000-06-12       Impact factor: 4.164

3.  Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease.

Authors:  M E Wittekoek; E de Groot; M H Prins; M D Trip; H R Büller; J J Kastelein
Journal:  Atherosclerosis       Date:  1999-10       Impact factor: 5.162

Review 4.  Statin therapy and stroke prevention.

Authors:  C J Vaughan; N Delanty; C T Basson
Journal:  Curr Opin Cardiol       Date:  2001-07       Impact factor: 2.161

Review 5.  Optimal management of familial hypercholesterolemia: treatment and management strategies.

Authors:  Mohammad Hassan Nemati; Behrooz Astaneh
Journal:  Vasc Health Risk Manag       Date:  2010-12-03

6.  Risk of brain infarction in familial hypercholesterolemia.

Authors:  M Kaste; P Koivisto
Journal:  Stroke       Date:  1988-09       Impact factor: 7.914

Review 7.  Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia.

Authors:  Fernando Civeira
Journal:  Atherosclerosis       Date:  2004-03       Impact factor: 5.162

8.  Risk of fatal stroke in patients with treated familial hypercholesterolemia: a prospective registry study.

Authors:  R R Huxley; M H Hawkins; S E Humphries; F Karpe; H A W Neil
Journal:  Stroke       Date:  2003-01       Impact factor: 7.914

9.  Simultaneous bilateral carotid stenting in a series of 9 patients: a single-center experience with review of literature.

Authors:  Anand Alurkar; Lakshmi Sudha Prasanna Karanam; Suresh Nayak; Sagar Oak
Journal:  J Clin Imaging Sci       Date:  2012-12-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.